Literature DB >> 31857216

5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence ureterorenoscopy for urinary upper tract urothelial carcinoma ∼Preliminary prospective single centre trial∼.

Hideo Fukuhara1, Atsushi Kurabayashi2, Mutsuo Furihata2, Shouhei Setuda3, Kiwamu Takahashi3, Kiyotaka Murakami3, Toru Tanaka3, Keiji Inoue4.   

Abstract

OBJECTIVE: To investigate the diagnostic accuracy of 5- aminolevulinic acid-mediated photodynamic diagnosis (ALA-PDD) for upper urinary tract tumor (UTUC) including carcinoma in situ (CIS) lesions using flexible fluorescence ureterorenoscopy.
METHODS: A solution of ALA was orally administrated at 20 mg/kg body weight at 3 h prior to surgery. Fluorescence observation was carried out with IMAGE1S OPAL1 PDD system. Positive lesions that were identified as abnormal changes under white light and/or blue light were biopsied, followed by cold-cup biopsy of negative lesions that were normal-looking mucosa under white light and/or blue light. Diagnostic accuracy was analysed by comparing ureterorenoscopic observations under white light or blue light with pathological analysis results.
RESULTS: A total of 31 biopsy specimens were obtained from 10 patients. The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for PDD to detect UTUC was 100 %, 50 %, 52.4 % and 100 %, respectively. The sensitivity of PDD ureterorenoscopy was significantly higher than that of white light ureterorenoscopy by statistics (p < 0.05). Especially, 5 CIS lesions were detected only by ALA-PDD ureterorenoscopy (p < 0.05). Of 10 patients, one patient (10 %) experienced hypotension during the ALA-PDD.
CONCLUSIONS: ALA-PDD for UTUC is a feasible and safe techniques with acceptable adverse events. Additional advantage of ALA-PDD for UTUC is the high sensitivity to detect CIS lesions with blue light mode.
Copyright © 2019 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  5-aminolevulinic acid; Photodynamic diagnosis; Ureterorenoscopy; Urinary upper tract urothelial carcinoma

Year:  2019        PMID: 31857216     DOI: 10.1016/j.pdpdt.2019.101617

Source DB:  PubMed          Journal:  Photodiagnosis Photodyn Ther        ISSN: 1572-1000            Impact factor:   3.631


  4 in total

Review 1.  5-Aminolevulinic Acid-Induced Protoporphyrin IX Fluorescence Imaging for Tumor Detection: Recent Advances and Challenges.

Authors:  Yoshinori Harada; Yasutoshi Murayama; Tetsuro Takamatsu; Eigo Otsuji; Hideo Tanaka
Journal:  Int J Mol Sci       Date:  2022-06-09       Impact factor: 6.208

Review 2.  Developments in Vascular-Targeted Photodynamic Therapy for Urologic Malignancies.

Authors:  Lucas Nogueira; Andrew T Tracey; Ricardo Alvim; Peter Reisz; Avigdor Scherz; Jonathan A Coleman; Kwanghee Kim
Journal:  Molecules       Date:  2020-11-19       Impact factor: 4.411

3.  A prospective, single-arm trial of fluorescent ureteroscopy-assisted thulium-holmium:YAG dual laser ablation for upper urinary tract cancer: Study protocol of the FLUAM trial.

Authors:  Makito Miyake; Takashi Yoshida; Nobutaka Nishimura; Yuki Oda; Takuto Shimizu; Tomonori Nakahama; Shunta Hori; Yosuke Morizawa; Daisuke Gotoh; Yasushi Nakai; Satoshi Anai; Kazumasa Torimoto; Tomomi Fujii; Nobumichi Tanaka; Kiyohide Fujimoto
Journal:  Contemp Clin Trials Commun       Date:  2022-03-02

Review 4.  Current status of photodynamic technology for urothelial cancer.

Authors:  Keiji Inoue; Hideo Fukuhara; Shinkuro Yamamoto; Takashi Karashima; Atsushi Kurabayashi; Mutsuo Furihata; Kazuhiro Hanazaki; Hung Wei Lai; Shun-Ichiro Ogura
Journal:  Cancer Sci       Date:  2021-12-02       Impact factor: 6.716

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.